ERAS

Conviction 50HealthcareScan · Thu, Sep 24, 2026

Erasca, Inc. (ERAS) closed at $14.51 (+4.02%) on Sep 24, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 37, RS Rating 99, -35.4% from its 52-week high, +304.0% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.

ERAS$14.51+4.02%

ResistanceSupportVol 14

Vol MA14 5.71M

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

Erasca, Inc.PHARMACEUTICAL PREPARATIONSwww.erasca.com ↗

Price14.51

Change+4.02%

Gap-0.04%

Rel volume3.17×

Avg volume5.37M

Avg $ vol84.9M

SMA 2016.09

SMA 5017.48

SMA 20013.65

Price vs 50-17.03%

Price vs 200+6.27%

MA stackmixed

50/200 cross—

Supertrenddown · 17.69

RSI (14)37

MACD hist-0.14

MACD cross—

Stoch %K / %D26 / 21

ADX (14)17

+DI / −DI13 / 25

RSI divergence—

MACD divergence—

ATR %7.77%

ADR %6.88%

52w high22.47

52w low1.81

From 52w high-35.45%

Above 52w low+701.38%

New 52w highNo

SqueezeOff

Bollinger width30.80%

%B0.18

Donchian pos14.07%

Donchian high20.40

Donchian low13.54

AVWAP (52w high)15.10

vs AVWAP high-3.93%

AVWAP (52w low)12.55

vs AVWAP low+15.55%

OBV trendFlat

Chaikin MF (20)-0.21

Today vs 20d3.17×

Avg vol (14d)5.71M

Avg vol (20d)5.37M

Avg $ vol (20d)84.9M

Market cap5.07B

RS Rating99 / 99

RS 3m (vs SPY)-7.47%

RS 6m (vs SPY)-26.10%

RS line new highNo

Trend template4/8

Technical rank36.4

1 week-5.44%

1 month-18.33%

3 months-2.98%

6 months-9.29%

1 year+719.49%

YTD+304.04%

P/E-40.73

P/B14.02

P/S—

P/FCF-53.08

EPS-0.4400

Div yield—

ROE-34.42%

ROA-28.63%

Debt/Eq—

Current8.29

EV/EBITDA-36.51

Gross margin—

Net margin—

Rev growth—

EPS growth22.95%

Price target24.13

Target upside66.36%

Analyst ratingBuy

Institutional84.87%

Ent. value5.03B

Revenue—

Net income-44.08M

Gross profit—

Free cash flow-95.58M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out310.98M

Employees103

ListedFri, Jul 16, 2021

Free float219.65M

Float %77.4%

Short interest31.24M

Days to cover9.4d

Short volume56.7%

Squeeze score80 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.14 vs −$0.12

Last surprise-16.7% miss

Setup gradeC

Conviction50 / 100

Pattern quality—

Tech rank36.4 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance19.81

Support14.94

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ERAS

All disclosures →

No recent disclosed trades by Congress in ERAS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ERAS

Insider	Side	Shares	Value	Traded	Filed
Fuchs Charles S. President, R&D · Stock option (right to buy) · 2026-08-10	Grant	1.3M	—	2026-08-10	2026-08-12
Hambleton Julie Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29
Bristol James Arthur Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29
LIU JEAN I Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29
Casdin Alexander W. Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29
Multani Pratik S Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29
Start Valerie Denise Harding Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29

SEC filings

EDGAR filings in ERAS · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.

ERAS

Recent news

Get daily signals & real-time alerts.